≥65 years; all participants | ≥65 years; underlying disease | ≥65 years; without underlying disease | ||||||||||
The mean follow-up period (year) | 10.12 | 9.52 | 11.3 | |||||||||
The mean follow-up period until death | 9.04 | 8.69 | 9.9 | |||||||||
All participants/ death (N) | 9978/6548 | 6668/4661 | 3310/1887 | |||||||||
n | No. of deaths | HR | 95% CI | n | No. of deaths | HR | 95% CI | n | No. of deaths | HR | 95% CI | |
BMI category | ||||||||||||
-18.5 | 249 | 205 | 1.50 | (1.29 - 1.74)* | 160 | 136 | 1.60 | (1.33 - 1.91)* | 89 | 69 | 1.47 | (1.13 - 1.89)* |
18.5 - 22.5 | 1777 | 1265 | 1.15 | (1.07 - 1.24)* | 1041 | 804 | 1.18 | (1.07 - 1.29)* | 736 | 461 | 1.18 | (1.04 - 1.35)* |
22.5 - 25 | 2280 | 1529 | 1.00 | (ref) | 1468 | 1065 | 1.00 | (ref) | 812 | 464 | 1.00 | (ref) |
25 - 30 | 3980 | 2529 | 0.94 | (0.88 - 1.00)* | 2700 | 1839 | 0.92 | (0.85 - 0.99)* | 1280 | 690 | 0.93 | (0.82 - 1.04) |
30 - 35 | 1280 | 767 | 0.97 | (0.89 - 1.06) | 970 | 606 | 0.91 | (0.82 - 1.01) | 310 | 161 | 0.96 | (0.80 - 1.14) |
35- | 412 | 253 | 1.22 | (1.07 - 1.39)* | 329 | 211 | 1.16 | (1.00 - 1.34) | 83 | 42 | 1.04 | (0.75 - 1.41) |